Dr. Siddhartha Kadia to Join NuVasive Board of Directors
NuVasive (NASDAQ: NUVA) has appointed Dr. Siddhartha Kadia to its Board of Directors as of February 1, 2021. Dr. Kadia brings over 20 years of experience in medical technology, notably as former CEO of EAG Laboratories, acquired for $780 million in 2017. His expertise includes marketing and operations with Life Technologies, overseeing a $2 billion product portfolio. CEO Christopher Barry emphasizes Dr. Kadia's leadership in innovation and growth as valuable for advancing NuVasive's mission to transform surgery and improve patient outcomes. Dr. Kadia aims to enhance NuVasive's long-term strategy and shareholder value.
- Appointment of Dr. Siddhartha Kadia expected to bring fresh perspectives and extensive leadership to the Board.
- Dr. Kadia's background in medical technology and innovation aligns with NuVasive's goals of transforming surgery and improving outcomes.
- Potential concerns over continuity in leadership with the introduction of a new board member.
- Experience gaps could arise as the company adapts to Dr. Kadia's vision and strategic direction.
SAN DIEGO, Feb. 1, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointment of Siddhartha Kadia, Ph.D. to the Company's Board of Directors, effective February 1, 2021.
Dr. Kadia has more than 20 years of experience in the medical technology industry with expertise in globally commercializing disruptive technology. He most recently served as president and CEO of EAG Laboratories, a global scientific services company providing analytical testing and consulting solutions, which was acquired by Eurofins Scientific for
"Siddhartha's extensive leadership experience in bringing innovation to market and driving growth across global regions is well suited to support our purpose to transform surgery, advance care, and change lives," said J. Christopher Barry, chief executive officer of NuVasive. "This expertise, coupled with his knowledge of leading successful medical technology organizations, makes Siddhartha a great addition to our Board of Directors."
"I'm passionate about improving our healthcare system and bringing technology to market that will help improve clinical, operational, and financial outcomes for surgeons, providers, and most importantly—for patients," said Dr. Kadia. "I look forward to helping NuVasive deliver on its long-term strategy and value to its shareholders."
Prior to EAG Laboratories, Dr. Kadia spent nine years with Life Technologies Corporation and its predecessor Invitrogen Corporation. Dr. Kadia held various positions with increasing responsibilities, including marketing and operations roles, as well as leadership roles in Japan and China. Most notably, he served as President, Life Sciences Division at Life Technologies where he managed a
Dr. Kadia earned a B.E. in electronics and telecommunications from Gujarat University in India, an M.S. in biomedical engineering from Rutgers University, and a Ph.D. in biomedical engineering from Johns Hopkins University. He is currently a board member of ALS Limited and BioSkryb. Dr. Kadia's board experience also includes prior public company board service as a director of Volcano Corporation, Newport Corporation, and Horizon Discovery Group plc.
About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company's less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company's comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than
Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products, the Company's ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
View original content to download multimedia:http://www.prnewswire.com/news-releases/dr-siddhartha-kadia-to-join-nuvasive-board-of-directors-301219380.html
SOURCE NuVasive, Inc.
FAQ
Who is Siddhartha Kadia and what is his background?
What impact could Dr. Kadia's appointment have on NuVasive?
When did Dr. Kadia join the NuVasive Board of Directors?
What are NuVasive's main goals with the new board appointment?
